Samsung Bioepis-3SBio deal to aid China biosimilar business expansion
Category: #health  By Shikha Sinha  Date: 2019-01-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Samsung Bioepis-3SBio deal to aid China biosimilar business expansion

In a recent turn of events, Samsung Bioepis Co. has reportedly announced the expansion of its rapidly growing biosimilar business into China via a licensing agreement with 3SBio Inc. As per trusted sources, the agreement encloses Samsung Bioepis’ multiple biosimilar candidates including SB8, a biosimilar candidate referring to AVASTIN (bevacizumab).

As per the agreement, the two companies will work together in a number of areas, comprising clinical development, commercialization in China, and regulatory registration. Samsung Bioepis will be entitled to receive upfront payment, milestone payment, as well as royalties on sales, cite sources close to the deal.

Christopher Hansung KO, President and CEO of Samsung Bioepis, said in a statement that the company is rather thrilled to grow its biosimilar business into China, where it hopes to see its business play a significant role in expanding patient access to premium-quality healthcare services. Also, the firm believes that it can realize this goal through partnership with 3SBio, which merges Samsung Bioepis’ notable development platform with 3SBio’s robust commercialization platform, the President added.

He further mentioned that the company will continue its enduring commitment to biosimilars by strengthening its pipeline and augmenting its availability for patients and healthcare systems throughout the world.

Presently, Samsung Bioepis has four biosimilars approved and marketed throughout Europe, while in the United States it has only RENEFLEXIS biosimilar approved and marketed with two more candidates undergoing regulatory review, cite credible sources. In all, more than 100,000 patients throughout the world are presently undergoing treatment through Samsung Bioepis’ biosimilars with more than 6 million administered doses, reported sources.

For the record, 3SBio is a full-fledged Chinese biotechnology company with the market’s leading biopharmaceutical franchises in auto-immune diseases, oncology, metabolic diseases, nephrology, and dermatology. The company is committed towards the development of an innovative product pipeline, with more than 30 products candidates currently under development. 3SBio’s production capabilities comprise of recombinant proteins, chemically synthesized molecules, and monoclonal antibodies with productions centers in prominent locations like Shanghai, Shenyang, Shenzhen, Hangzhou, and Cumo, Italy.    



About Author

Shikha Sinha

Email: [email protected]   

Shikha Sinha

Shikha currently manages content operations for a series of news and business portals including MSF, Algosonline, and the like. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market resea...

Read More

More News By Shikha Sinha

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Shikha Sinha

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Shikha Sinha

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
By Shikha Sinha

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patient...